clinical trials
-
Long COVID affects millions of children. The largest pediatric trial so far launches this year.
One NIH study will test low-dose naltrexone, while other upcoming trials will test larozitide and taurine.
-
Research updates, February 3
The Food and Drug Administration (FDA) has granted expanded access to the stem cell infusion RegeneCyte for Long COVID.
-
Research updates, January 27
A large prospective cohort study published in Infectious Diseases found that a majority of people with Long COVID did not recover.
-
New RECOVER-TLC trials won’t enroll until summer. Nearly two years after the program’s launch.
The RECOVER-Treating Long COVID initiative is set to begin enrolling participants in new clinical trials this summer, which will mark nearly two years after the National of Institutes of Health (NIH) effort launched with promises to deliver greater urgency for this chronic disease impacting tens of millions of Americans.
-
Research updates, January 20
A new study in eBioMedicine found neurological Long COVID symptoms were associated with increased pTau-181 levels, a marker of brain inflammation that has been tied to Alzheimer’s disease.
-
Severe people may hold answers to Long COVID. They must be included in research.
People with the most severe symptoms represent the most clinically urgent population, yet they remain absent from the evidence base that guides care. Their exclusion is not a procedural oversight but a scientific failure, and correcting it is essential for any program committed to understanding the full spectrum of the disease.
-
Research updates, January 13
A large, electronic health records study published in JAMA Internal Medicine estimated that over 100,000 Americans died each year between 2022 and 2024 from COVID-19.
-
Research updates, January 6
43% of Latino people reported symptoms of Long COVID in a new survey study published in Journal of General Internal Medicine. The survey included the responses of 1,500 participants in Washington state who had confirmed COVID-19 cases between 2020 and 2022.
-
Research updates, December 23
Two recent studies state that Long COVID is an occupational disease.
-
Despite Long COVID’s ongoing impact, research in Colombia is limited
One of the few Long COVID research studies in Colombia is testing cognitive rehabilitation therapy. This approach recently failed in a U.S. clinical trial.
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
-
Long COVID affects millions of children. The largest pediatric trial so far launches this year.
-
Research updates, February 3
-
National COVID-19 trends, February 3
-
Snapshots of the unseen: How we focused Long COVID in a recent photo exhibition
-
Metrodora promised comprehensive treatment. But within two years, it abruptly closed.
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS national COVID-19 trends NIH NIH RECOVER podcast public health Q&A research update science Trump administration updates and events vaccines wastewater surveillance